Aptevo Therapeutics Inc. Announces 2024 Annual Meeting of Stockholders on June 7
Ticker: APVO · Form: DEF 14A · Filed: Apr 23, 2024 · CIK: 1671584
| Field | Detail |
|---|---|
| Company | Aptevo Therapeutics Inc. (APVO) |
| Form Type | DEF 14A |
| Filed Date | Apr 23, 2024 |
| Risk Level | low |
| Pages | 16 |
| Reading Time | 19 min |
| Key Dollar Amounts | $15,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: Proxy Statement, Annual Meeting, Stockholders, Board of Directors, Executive Compensation
TL;DR
<b>Aptevo Therapeutics Inc. will hold its virtual Annual Meeting of Stockholders on June 7, 2024, to vote on director elections, auditor ratification, stock incentive plan approval, and executive compensation.</b>
AI Summary
Aptevo Therapeutics Inc. (APVO) filed a Proxy Statement (DEF 14A) with the SEC on April 23, 2024. Aptevo Therapeutics Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 7, 2024, at 10 a.m. Pacific Time. The meeting agenda includes electing two directors, ratifying Moss Adams LLP as the independent auditor for 2024, and approving the Second Amended and Restated 2018 Stock Incentive Plan. Stockholders will also vote on a non-binding advisory basis regarding the compensation of named executive officers for 2023. The record date for determining stockholders entitled to vote is April 17, 2024. The company is a pharmaceutical preparations company based in Seattle, WA.
Why It Matters
For investors and stakeholders tracking Aptevo Therapeutics Inc., this filing contains several important signals. The virtual format aims to facilitate stockholder participation and save costs. Key proposals include electing directors and approving the company's stock incentive plan, which are critical for governance and future equity compensation.
Risk Assessment
Risk Level: low — Aptevo Therapeutics Inc. shows low risk based on this filing. The filing is a routine proxy statement (DEF 14A) and does not contain new financial or operational disclosures that would indicate immediate risk.
Analyst Insight
Stockholders should review the proxy materials carefully to make informed voting decisions on director nominees, auditor ratification, stock incentive plans, and executive compensation.
Key Numbers
- June 7, 2024 — Annual Meeting Date (2024 Annual Meeting of Stockholders)
- April 17, 2024 — Record Date (For determining stockholders eligible to vote)
- 2026 — Director Term End (Directors to hold office until the 2026 Annual Meeting)
- 2024 — Auditor Fiscal Year (Independent registered public accounting firm for the year ending December 31, 2024)
Key Players & Entities
- Aptevo Therapeutics Inc. (company) — Registrant and filer of the proxy statement
- June 7, 2024 (date) — Date of the Annual Meeting of Stockholders
- Moss Adams LLP (company) — Proposed independent registered public accounting firm
- April 17, 2024 (date) — Record date for determining stockholders entitled to vote
- 2018 Stock Incentive Plan (plan) — Plan to be approved by stockholders
FAQ
When did Aptevo Therapeutics Inc. file this DEF 14A?
Aptevo Therapeutics Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 23, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Aptevo Therapeutics Inc. (APVO).
Where can I read the original DEF 14A filing from Aptevo Therapeutics Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Aptevo Therapeutics Inc..
What are the key takeaways from Aptevo Therapeutics Inc.'s DEF 14A?
Aptevo Therapeutics Inc. filed this DEF 14A on April 23, 2024. Key takeaways: Aptevo Therapeutics Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 7, 2024, at 10 a.m. Pacific Time.. The meeting agenda includes electing two directors, ratifying Moss Adams LLP as the independent auditor for 2024, and approving the Second Amended and Restated 2018 Stock Incentive Plan.. Stockholders will also vote on a non-binding advisory basis regarding the compensation of named executive officers for 2023..
Is Aptevo Therapeutics Inc. a risky investment based on this filing?
Based on this DEF 14A, Aptevo Therapeutics Inc. presents a relatively low-risk profile. The filing is a routine proxy statement (DEF 14A) and does not contain new financial or operational disclosures that would indicate immediate risk.
What should investors do after reading Aptevo Therapeutics Inc.'s DEF 14A?
Stockholders should review the proxy materials carefully to make informed voting decisions on director nominees, auditor ratification, stock incentive plans, and executive compensation. The overall sentiment from this filing is neutral.
Risk Factors
- Compliance with SEC Regulations [low — regulatory]: The company must comply with all SEC rules and regulations regarding proxy solicitations and annual meetings.
- Virtual Meeting Format [low — operational]: Reliance on a virtual meeting format may present challenges in ensuring full and equitable participation for all stockholders.
- Stock Incentive Plan Approval [medium — financial]: Approval of the stock incentive plan is crucial for attracting and retaining talent, impacting future equity dilution and compensation costs.
Key Dates
- 2024-06-07: Annual Meeting of Stockholders — Stockholders will vote on key proposals including director elections and plan approvals.
- 2024-04-17: Record Date — Determines which stockholders are eligible to vote at the Annual Meeting.
Glossary
- DEF 14A
- Definitive Proxy Statement filed with the SEC. (This filing type indicates the company is providing final proxy materials to shareholders for an upcoming meeting.)
- Proxy Statement
- A document filed with the SEC that provides information to shareholders about matters to be voted on at a company meeting. (Essential for shareholders to understand the issues and make informed voting decisions.)
Filing Stats: 4,731 words · 19 min read · ~16 pages · Grade level 12.2 · Accepted 2024-04-23 16:05:09
Key Financial Figures
- $15,000 — kapi Partners, Inc. a fee not to exceed $15,000 plus costs and expenses. In addition, O
Filing Documents
- apvo-2024-def14a_-_proxy.htm (DEF 14A) — 1326KB
- img167027806_0.jpg (GRAPHIC) — 44KB
- img167027806_1.jpg (GRAPHIC) — 44KB
- img167027806_2.jpg (GRAPHIC) — 44KB
- img167027806_3.jpg (GRAPHIC) — 44KB
- img167027806_4.jpg (GRAPHIC) — 44KB
- img167027806_5.jpg (GRAPHIC) — 47KB
- img167027806_6.jpg (GRAPHIC) — 44KB
- img167027806_7.jpg (GRAPHIC) — 44KB
- img167027806_8.jpg (GRAPHIC) — 44KB
- img167027806_9.jpg (GRAPHIC) — 6KB
- img167027806_10.jpg (GRAPHIC) — 41KB
- img167027806_11.jpg (GRAPHIC) — 156KB
- img167027806_12.jpg (GRAPHIC) — 452KB
- img167027806_13.jpg (GRAPHIC) — 394KB
- 0000950170-24-046881.txt ( ) — 3319KB
Security Ownership of Certain Beneficial Owners and Management
Security Ownership of Certain Beneficial Owners and Management 40 Executive Officers 42
Executive Compensation
Executive Compensation 43 Transactions With Related Persons 53 Householding of Proxy Materials 54 Other Matters 55 APPENDIX A A- 1 APTEVO THERAPEUTICS INC. 2401 4th Avenue, Suite 1050 Seattle, Washington 98121 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS To be held on June 7, 2024 QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING Why did I receive a notice regarding the availability of proxy materials on the internet? Pursuant to rules adopted by the Securities and Exchange Commission (the “SEC”), we have elected to provide access to our proxy materials over the internet. Accordingly, we have sent you a Notice of Internet Availability of Proxy Materials (the “Notice”) because the Board of Directors (the “Board”) of Aptevo Therapeutics Inc. (sometimes referred to as the “Company,” “Aptevo,” “we,” “us” or “our”) is soliciting your proxy to vote at the 2024 Annual Meeting of Stockholders (the “Annual Meeting”), including at any adjournments or postponements of the meeting. All stockholders will have the ability to access the proxy materials on the website referred to in the Notice or request to receive a printed set of the proxy materials. Instructions on how to access the proxy materials over the internet or to request a printed copy may be found in the Notice. We intend to mail the Notice on or about April 23 , 2024 to all stockholders of record entitled to vote on the proposals being presented at the Annual Meeting. How do I attend the Annual Meeting? In order to facilitate stockholder participation and save costs, the meeting will be held virtually on June 7, 2024 at 10 a.m. Pacific Time. There will not be a physical meeting . We have worked to offer the same participation opportunities as if you attended the Annual Meeting in person and hope the virtual format will allow mo